Pharmiweb.com

2 weeks ago | pharmiweb.com | Mike Wood

Breaking into or advancing within medical writing in the UK and Europe requires more than just a strong scientific background — employers look for candidates who can communicate complex data clearly, understand industry regulations, and collaborate effectively. This guide covers the top interview questions you're likely to encounter, with expert tips on how to answer them, and direct links to current opportunities on PharmiWeb.Jobs. 1.

2 weeks ago | pharmiweb.com | Mike Wood

Disclaimer: You are now leaving PharmiWeb.com website and are going to a website that is not operated by us. We are not responsible for the content or availability of linked sites. ABOUT THIRD PARTY LINKS ON OUR SITE PharmiWeb.com offers links to other third party websites that may be of interest to our website visitors. The links provided in our website are provided solely for your convenience and may assist you in locating other useful information on the Internet.

3 weeks ago | pharmiweb.com | Zac Amos

Pharmaceutical laboratories and life-science manufacturers sit on a goldmine of intellectual property and patient data. Cybercriminals know this. Their favorite entry tactic is the humble phishing email — now turbo-charged with social engineering tricks and mobile delivery channels. Taking care of the problem requires closely evaluating present and emerging threats and devising a multi-layered defense strategy.

1 month ago | pharmiweb.com | Sue Charles

Hadfield, UK and Hong Kong, China – 13 May 2025 – UK genomics tools company, RevoluGen Limited and Hong Kong-based life sciences distributor ProteoQuest Technology Co. Ltd are pleased to announce they have entered into an agreement for the distribution of Fire Monkey™ High Molecular Weight (HMW) DNA extraction kits across China, including Hong Kong and Taiwan.

1 month ago | pharmiweb.com | Zac Amos

Patient payment processes in pharma can be disjointed and overly complex. This can cause higher therapy abandonment rates and unnecessary delays in treatment. Rising out-of-pocket costs only add to the burden, making it harder for individuals to start or stay on prescribed medications. Pharma companies that fail to address these friction points risk losing trust, revenue and long-term adherence.